Kidney Cancer

The Food and Drug Administration granted a Biologics License Application for subcutaneous Opdivo for potential approval.

This is the poem I wrote to help myself cope with my new diagnosis. It served as a reminder that I was resilient.

For decades, researchers have been seeking a therapy to improve outcomes for patients with clear cell renal cell carcinoma who underwent a nephrectomy.

Anxiety over scans makes sense, but isn’t there more anxiety about other cancer tests, too?

Across disease stages, Black patients with renal cell carcinoma experience worse survival outcomes than White patients, research has shown.

Patients with inoperable kidney cancer saw significant results in local control and cancer-specific survival with stereotactic ablative body radiotherapy.

Subcutaneous administration of Opdivo, could increase efficiency and reduce wait times for patients, as one expert explains to CURE®.

When life hands you cancer lemons, what flavored lemonade do you make?

Researchers have determined distinguishing characteristics of TFE3-rearranged renal cell carcinoma.

Artificial intelligence platform ChatGPT is capable of providing “widely understandable and accessible” answers about kidney cancer, but experts express caution.

Welireg outperformed Afinitor in time to disease progression and patient-reported quality of life in the treatment of metastatic clear cell renal cell carcinoma.

Real-world data demonstrated that knowing a patient’s stage and subtype of renal cell carcinoma, a type of kidney cancer, may provide cancer teams with the information needed to determine potential prognosis and recurrence risk.

Subcutaneous Opdivo led to similar outcomes to intravenous administration of the drug and may be easier to access down the road, an expert said.

Patients with clear cell renal cell carcinoma had improved overall survival when treated with adjuvant Keytruda compared to placebo.

Opdivo failed to improve disease-free survival in patients with localized renal cell carcinoma at high risk of relapse, according to findings from CheckMate 914.

After cancer, taking baby steps towards stuff you want to do is what matters.

Some with metastatic cancers receiving end-of-life-initiated immunotherapy may have a decreased risk of mortality when treated at a high-volume facility, research found.

Recently, I have been focusing on the concept of Mattering, and it has boosted my mental health.

We all know that stress is bad.

Treatment with Welireg — now approved by the FDA — helped shrink and stabilize tumors from metastatic renal cell carcinoma with minimal side effects, a patient told CURE®.

The Food and Drug Administration has approved Welireg for patients with advanced renal cell carcinoma, a type of kidney cancer, following treatment with a PD-1 or PD-L1 inhibitor and a VEGF-TKI.

I have cancer and don't believe in god, can I still be spiritual?

The Welireg-Cabometyx treatment combination demonstrated anti-tumor activity for some patients with clear cell renal carcinoma, according to a phase 2 trial.

Patients with advanced clear cell renal cell carcinoma treated with zanzalintinib had experienced promising antitumor activity with manageable toxicity regardless of prior treatment with cabozantinib.

Researchers continue to investigate novel immunotherapy drugs for the treatment of renal cell carcinoma.

Although research has delved into the potential link between clonal hematopoiesis and heart-related events such as heart attacks and strokes in patients with kidney cancer, more research is needed to further understand this association.

Circulating tumor DNA — which is observed via blood test — may be helpful in determining which patients with kidney cancer need more intense treatment and who can have their therapies deescalated.

While translocation renal cell carcinoma tends to respond well to immunotherapy, there is still a need for more investigation into targeted therapies for this patient population.

Welireg led to improved time to progression and objective response rates compared to Afinitor for patients with advanced clear cell renal cell carcinoma, according to study findings.